SAR407899
Total Payments
$111,125
Transactions
196
Doctors
10
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $37,884 | 26 | 0 |
| 2018 | $55,671 | 64 | 3 |
| 2017 | $17,570 | 106 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $68,042 | 172 | 61.2% |
| Consulting Fee | $43,008 | 22 | 38.7% |
| Travel and Lodging | $75.00 | 2 | 0.1% |
Payments by Type
Research
$68,042
172 transactions
General
$43,083
24 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients With Microvascular Angina and/or Persistent Stable Angina Despite Angiog | SANOFI US SERVICES INC. | $56,619 | 0 |
| A Dose Titration Study to Assess the Effects of SAR407899 in Patients With Microvascular Angina and/or Persistent Stable Angina Despite Angiographically Successful Elective PCI. | SANOFI US SERVICES INC. | $8,988 | 8 |
| A Dose Titration Study to Assess the Effects of SAR407899 in Patients With Microvascular Angina and/or Persistent Stable Angina Despite Angiographically Successful Elective PCI | SANOFI US SERVICES INC. | $2,095 | 0 |
| Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia | SANOFI US SERVICES INC. | $340.20 | 0 |
Top Doctors Receiving Payments for SAR407899
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $65,289 | 95 |
| , M.D | Nuclear Cardiology | Boston, MA | $28,723 | 17 |
| , MD | Diagnostic Radiology | Boston, MA | $6,750 | 2 |
| , M.D | Nephrology | Baltimore, MD | $2,708 | 5 |
| , MD | Internal Medicine | Los Angeles, CA | $1,555 | 15 |
| , M.D | Student in an Organized Health Care Education/Training Program | Atlanta, GA | $1,467 | 12 |
| , M.D | Internal Medicine | Sacramento, CA | $1,257 | 18 |
| , M.D | Cardiovascular Disease | Los Angeles, CA | $1,177 | 10 |
| , MD | Cardiovascular Disease | Houston, TX | $1,063 | 11 |
| , MD | Internal Medicine | Philadelphia, PA | $938.73 | 8 |
| , MD | Cardiovascular Disease | Wellington, FL | $197.54 | 3 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $103,557
- SANOFI-AVENTIS U.S. LLC $7,097
- sanofi-aventis U.S. LLC $471.00
Product Information
- Type Drug
- Total Payments $111,125
- Total Doctors 10
- Transactions 196
About SAR407899
SAR407899 is a drug associated with $111,125 in payments to 10 healthcare providers, recorded across 196 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2019. In 2019, $37,884 was paid across 26 transactions to 0 doctors.
The most common payment nature for SAR407899 is "Unspecified" ($68,042, 61.2% of total).
SAR407899 is associated with 4 research studies, including "A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients With Microvascular Angina and/or Persistent Stable Angina Despite Angiog" ($56,619).